EN DE
Watch Astec LifeSciences Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Astec LifeSciences Limited (ASTEC) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Astec LifeSciences Limited stock ₹421, price ₹553, that is 23.9% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN · ISIN INE563J01010

AL Astec LifeSciences Limited logo Thin data Nov 16, 2026

Astec LifeSciences Limited

ASTEC · NSE

Expensive (fair value 24% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Fair value ₹420.96 · Overvalued 
Quality 38/100 
Weak Growth (revenue 5y −4.2 %/yr in INR) 
Loss-making · -18.1% net margin (TTM) 
Negative free cash flow 
Trails peers (0/10) 
Narrow moat 12/100
Thin data 
⟳ CyclicalEstimate
Watch Astec LifeSciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹2,248 ₹521.85 Fair Value ₹420.96 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ₹521.85 – ₹2,248 · fair‑value band ₹315.72 – ₹526.20 · the ₹553.40 price screens above the ₹420.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Astec LifeSciences in your weekly email

Every Wednesday you see whether Astec LifeSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India.

Show moreShow less

The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservatives.

It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited operates as a subsidiary of Godrej Agrovet Limited.

Stock analysis

Astec LifeSciences Limited (ASTEC) currently trades at ₹553.40, while our estimate is ₹420.96, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹315.72 (bear) to ₹526.20 (bull), the price of ₹553.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Astec LifeSciences Limited reported revenue of ₹4.5B in FY2026 versus ₹6.8B in FY2022, a compound −9.8%/yr. Reported net income was −₹809M in FY2026.

Key figures

Market cap ₹12.3B (≈ $131M) Micro · P/S ratio 2.95 · EPS (TTM) ₹−35.71 · Net margin −18.1% · Return on equity −21.2% · Return on assets (EBIT) −0.8% (5-year average) · Operating margin −41.8% · Revenue (TTM) ₹4.4B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 40% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 10% fair-value upside, at −24%, ASTEC screens richer than that median.

Fair Value

Bear ₹315.72 Fair Value ₹420.96 Bull ₹526.20
Price ₹553.40 · Downside -23.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 89
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 34
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 30
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 19
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+17.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.2%
Start year 2021 (pandemic). Over 10 years: +5.6% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.7% (2021) → −11.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ASTEC screens overvalued: fair value 24% below the price. Compare with Nutrien Ltd →

Compare Astec LifeSciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 175 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −23.9% · Below median
Profitability
Return on assets −8.6% · Bottom 25%
Net margin (12 months) −18.1% · Bottom 25%
Operating margin (12 months) −41.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −1.5% · Below median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/B 3.16× · Priciest 25%
P/S (12 months) 2.81× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 17
FUTURE (revenue growth)0 · sector 17
PAST (return on equity)0 · sector 25
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
The Mosaic Company MOS $21.23 $28.58 +35% vs ASTEC
Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 ¥29.91 ¥38.01 +27% vs ASTEC
Qinghai Salt Lake Industry Co 000792 ¥21.62 ¥26.81 +24% vs ASTEC
Nutrien Ltd NTR $68.94 $83.09 +21% vs ASTEC
ICL Group ICL $4.41 $4.86 +10% vs ASTEC
Yara International ASA YAR kr 405.70 kr 424.51 +5% vs ASTEC
CF Industries Holdings CF $119.85 $114.88 −4% vs ASTEC
UPL Limited UPL ₹563.45 ₹478.29 −15% vs ASTEC
Yunnan Yuntianhua Co 600096 ¥26.06 ¥17.67 −32% vs ASTEC
Coromandel International Limited COROMANDEL ₹1,969 ₹1,129 −43% vs ASTEC

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Astec LifeSciences Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Astec LifeSciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/ASTEC

Frequently asked questions

Is Astec LifeSciences Limited (ASTEC) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ₹420.96 versus a price of ₹553.40, about 24% lower (overvalued).
What is the fair value of ASTEC?
Our estimate for Astec LifeSciences Limited is ₹420.96 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₹553.40.
What is the quality score of ASTEC?
Astec LifeSciences Limited has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Astec LifeSciences Limited (ASTEC)?
Our calculated price target is the estimate of ₹420.96 (as of Nov 16, 2026). Cautious scenario ₹315.72, optimistic scenario ₹526.20. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Astec LifeSciences Limited stock forecast for 2026?
Our estimate puts fair value at ₹420.96, about 24% lower versus a price of ₹553.40 (overvalued). Cautious scenario ₹315.72, optimistic scenario ₹526.20. The calculation is refreshed regularly with new filings.
What is the revenue of Astec LifeSciences Limited (ASTEC)?
Astec LifeSciences Limited reported trailing-twelve-month revenue of about ₹4.4B (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Astec LifeSciences Limited (ASTEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Astec LifeSciences Limited it is ₹420.96 per share (as of Nov 16, 2026), against a price of ₹553.40.
Is Astec LifeSciences Limited stock overvalued or undervalued in 2026?
As of Nov 16, 2026, ASTEC trades above its calculated fair value: price ₹553.40, fair value ₹420.96, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASTEC?
No. The price is what the market pays today (₹553.40); the fair value is what the company's own numbers justify (₹420.96). For Astec LifeSciences Limited the two are ₹132.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Astec LifeSciences Limited worth?
The market values Astec LifeSciences Limited at about ₹12.3B (market capitalisation, as of Nov 16, 2026). Per share that is ₹553.40; our models calculate a fair value of ₹420.96 per share.
What do the bullish and bearish scenarios say about ASTEC?
Our models span a range for Astec LifeSciences Limited: cautious scenario ₹315.72, base ₹420.96, optimistic ₹526.20 per share (as of Nov 16, 2026, price ₹553.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Astec LifeSciences Limited (ASTEC)?
Balance-sheet figures for Astec LifeSciences Limited (as of Nov 16, 2026): return on equity −21.2%, debt of 0.13 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ASTEC from its 52-week high?
Astec LifeSciences Limited trades at ₹553.40, about 40% below its 52-week high of ₹918.75 and 6% above the low of ₹521.85 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹420.96 is for.
Which stocks are comparable to Astec LifeSciences Limited?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Astec LifeSciences Limited stock attractive at the current price?
The data as of Nov 16, 2026: price ₹553.40, calculated fair value ₹420.96 (−24%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Astec LifeSciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Astec LifeSciences Limited (ASTEC)?
The closing price on Nov 16, 2026 was ₹553.40. Our estimate is ₹420.96, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Astec LifeSciences Limited right now?
The price sits above even our optimistic bull case (₹526.20). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Astec LifeSciences Limited

How large is the market capitalisation of Astec LifeSciences Limited (ASTEC)?
The market capitalisation of Astec LifeSciences Limited is ₹12.3B (≈ $131M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Astec LifeSciences Limited (ASTEC)?
The price-to-sales ratio of Astec LifeSciences Limited is 2.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Astec LifeSciences Limited (ASTEC)?
Earnings per share at Astec LifeSciences Limited are ₹−35.71. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Astec LifeSciences Limited (ASTEC)?
The net margin of Astec LifeSciences Limited is −18.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Astec LifeSciences Limited (ASTEC)?
The return on equity (ROE) of Astec LifeSciences Limited is −21.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Astec LifeSciences Limited (ASTEC)?
On an EBIT basis the return on assets of Astec LifeSciences Limited is −0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Astec LifeSciences Limited (ASTEC)?
The operating margin of Astec LifeSciences Limited is −41.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Astec LifeSciences Limited (ASTEC)?
Revenue at Astec LifeSciences Limited is down 1.5% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Astec LifeSciences Limited (ASTEC)?
Earnings per share at Astec LifeSciences Limited are down 96.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Astec LifeSciences Limited (ASTEC) generate?
The free cash flow of Astec LifeSciences Limited is −₹1.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Astec LifeSciences Limited (ASTEC) carry?
The net debt of Astec LifeSciences Limited is ₹4.4B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Astec LifeSciences Limited in the live analysis

One click puts Astec LifeSciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.